A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

NCT06612775 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Epilepsy

Interventions

DRUG: Test drug CB03-154 5mg group
DRUG: Test drug CB03-154 10mg group
DRUG: Test drug CB03-154 20mg group
DRUG: Placebo group

Sponsor

Shanghai Zhimeng Biopharma, Inc.